STAVUDINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H12N2O4
Molecular Weight	224.2133
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O

InChI

InChIKey=XNKLLVCARDGLGL-JGVFFNPUSA-N

InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C10H12N2O4
Molecular Weight	224.2133
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical
Record UNII	BO9LE4QFZF
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

STAVUDINE

Official Name

English

STAVUDINE [WHO-IP]

Common Name

English

STAVUDINE [MI]

Common Name

English

STAVUDINE [USAN]

Common Name

English

STAVUDINE (D4T) [VANDF]

Common Name

English

Showing 1 to 5 of 29 entries

Previous1 2 3 4 5 6Next

Show entries

Classification Tree

Code System

Code

Established Pharmacologic Class

NDF-RT

N0000175462

Reverse Transcriptase Inhibitors

NDF-RT

N0000009947

Analogs/Derivatives

NDF-RT

N0000175459

Antiretrovirals

WHO-ESSENTIAL MEDICINES LIST

6.4.2.3 (LAM/NEV/STA)

Reverse Transcriptase Inhibitor

NCI_THESAURUS

C97452

Showing 1 to 5 of 14 entries

Previous1 2 3Next

Show entries

Code System

Code

Type

Description

NSC

759897

PRIMARY

NCI_THESAURUS

C1428

PRIMARY

RXCUI

59763

PRIMARY

RxNorm

NSC

163661

PRIMARY

WIKIPEDIA

STAVUDINE

PRIMARY

Showing 1 to 5 of 24 entries

Previous1 2 3 4 5Next

Show entries

Related Record

Type

Details


					BO9LE4QFZF

STAVUDINE

EXCRETED UNCHANGED

Interaction Type:

AMOUNT EXCRETED

Qualification:

URINE

Amount:

67 % (average)
of dose


					A3Z87NSO0U

HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 POLYMERASE

TARGET -> INHIBITOR

Amount:


					859A956UY8

HUMAN IMMUNODEFICIENCY VIRUS TYPE 1

TARGET ORGANISM->INHIBITOR

Amount:

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Related Record

Type

Details


					KX2B81V402

N-ACETYL-L-CYSTEINE 2-DEOXY-3-THIO-D-ERYTHRO-PENTONIC ACID .GAMMA.-LACTONE THIOETHER

METABOLITE -> PARENT

Interaction Type:

MINOR

Qualification:

URINE

Amount:


					QR26YLT7LT

THYMINE

METABOLITE -> PARENT

Amount:


					1ZP0VJ751G

STAVUDINE TRIPHOSPHATE

METABOLITE ACTIVE -> PARENT

Comments:

The in vitro MIC (50% inhibitory concentration [IC50]) of d4T-TP against HIV-1 has been found to be between 0.009 and 6 μM, depending on the phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors.

Interaction Type:

MAJOR

Amount:

[0.009 to 6] MICROMOLAR (average)


					X4PT8NAI8E

STAVUDINE GLUCURONIDE

METABOLITE -> PARENT

Interaction Type:

MINOR

Qualification:

URINE

Amount:

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Related Record

Type

Details


					059QF0KO0R

WATER

IMPURITY -> PARENT

Comments:

Water (2.5.12): maximum 0.5 per cent, determined on 0.500 g.

Qualification:

EP

Amount:

[<0.5] % (limits)


					E37QXU5N74

THYMIDINE, 2',3'-DIDEHYDRO-3'-DEOXY-5'-O-(1,2,5-TRIDEOXY-1-(3,4-DIHYDRO-5-METHYL-2,4-DIOXO-1(2H)-PYRIMIDINYL)-.BETA.-D-THREO-PENTOFURANOS-5-YL)-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:

[<0.2] PERCENT PEAK AREA (limits)


					5Y0U269FPI

1-(4-(HYDROXYMETHYL)-2-OXO-2,5-DIHYDROFURAN-3-YL)-5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE

IMPURITY -> PARENT

Comments:

Amount Not Specified

Qualification:

INTERNATIONAL PHARMACOPEIA

Amount:


					J69N0KNC59

STAVUDINE.ALPHA.-ANOMER

IMPURITY -> PARENT

Comments:

Amount Not Specified

Qualification:

INTERNATIONAL PHARMACOPEIA

Amount:


					19TWX5TRJ4

3',5'-ANHYDROTHYMIDINE

IMPURITY -> PARENT

Comments:

Amount Not Specified

Qualification:

INTERNATIONAL PHARMACOPEIA

Amount:

Showing 1 to 5 of 14 entries

Previous1 2 3Next

Show entries

Related Record

Type

Details


					BO9LE4QFZF

STAVUDINE

ACTIVE MOIETY

Amount:

Showing 1 to 1 of 1 entries

Previous1Next

Name	Property Type	Amount	Parameters
Tmax	PHARMACOKINETIC	0.5 hours (average)	ORAL ADMINISTRATION

Biological Half-life	PHARMACOKINETIC	2.3 hours (average)	ORAL ADMINISTRATION